Pharma leaders often rush to launch pilots with new technology like VR without a sustainable engagement plan. This results in countless one-off projects that fail to scale. The crucial question isn't "Can we do it?" but "What happens after the first interaction?"

The industry's costly drug development failures are often attributed to clinical issues. However, the root cause is frequently organizational: siloed teams, misaligned incentives, and hierarchical leadership that stifle the knowledge sharing necessary for success.

Companies run numerous disconnected AI pilots in R&D, commercial, and other silos, each with its own metrics. This fragmented approach prevents enterprise-wide impact and disconnects AI investment from C-suite goals like share price or revenue growth. The core problem is strategic, not technical.

Pharma's primary AI challenge is not a lack of experimentation but a failure to execute, scale, and justify ROI. Launching additional pilots only accelerates the activity that keeps companies stuck, compounding the problem instead of solving it.

Many firms engage in "innovation theatre," building a portfolio of impressive but isolated AI pilots. Without a unifying strategic architecture connecting them to core growth objectives, these initiatives remain islands that fail to scale, compound, or move overall enterprise performance.

Many pharma companies allow various departments to run numerous, disconnected AI pilots without a central strategy. This lack of strategic alignment means most pilots fail to move beyond the proof-of-concept stage, with 85% yielding no measurable return on investment.

The increasing volume of new therapies requires pharma companies to stop treating each launch as a unique event. Instead, they must develop a scalable, repeatable, and excellent launch capability to handle the future pipeline efficiently and consistently.

Pharma companies engaging in 'pilotitis'—running random, unscalable AI projects—are destined to fall behind. Sustainable competitive advantage comes from integrating AI across the entire value chain and connecting it to core business outcomes, not from isolated experiments.

A primary driver of recent pharma launch failures is underinvestment in pre-launch market conditioning. Cautious investors and tighter budgets mean companies have fewer resources to tell their scientific story effectively before launch. This delayed and underfunded approach has a dramatic negative impact on commercial success.